A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Trial Details

NCT ID

NCT06544655

Phase

PHASE1

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

BMS-986484
Nivolumab
Oxaliplatin
Capecitabine
Fluorouracil
Calcium folinate

Locations (sample)

Tucson, Arizona, United States|32.22174,-110.92648
Los Angeles, California, United States|34.05223,-118.24368
Grand Rapids, Michigan, United States|42.96336,-85.66809
Sioux Falls, South Dakota, United States|43.54369,-96.72796
San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarci…
Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →